Tolvaptan, a selective arginine vasopressin receptor 2 (AVPR2) antagonist that inhibits cAMP production in response to AVP, is presently the only drug approved for the treatment of ADPKD. The gene discussed is AVP; the disease is autosomal dominant polycystic kidney disease.